Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics

Health Affairs

Volumn 30, Issue 12, 2011, Pages 2346-2354

  Vogt, William B ^a   Joyce, Geoffrey ^b   Xia, Jing ^c   Dirani, Riad ^d   Wan, George ^e   Goldman, Dana P ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c HARVARD UNIVERSITY   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e Janssen Services LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; COMPARATIVE EFFECTIVENESS; COST CONTROL; DRUG INFORMATION; DRUG USE; HEALTH SERVICE; HUMAN; MEDICAID;

EID: 84855707741     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2010.1296     Document Type: Article

References (19)

1. Crowley JS, Ashner D, Elam K. State Medicaid outpatient prescription drug policies: findings from a national survey, 2005 update [Internet]. Washington (DC): Kaiser Commission on Medicaid and the Uninsured; 2005 Oct [cited 2011 Oct 24]. Available from: http://www.kff.org/medicaid/upload/State-Medicaid-Outpatient-Prescription-Drug-Policies-Findingsfrom-a-National-Survey-2005-Update-report.pdf
2. Mello MM, Studdert DM, Brennan TA. The pharmaceutical industry versus Medicaid: limits on state initiatives to control prescription-drug costs. N Engl J Med. 2004;350:608-13.
3. Texas Health and Human Services Commission. Preferred drug list: annual report to the Texas legislature. Austin (TX): The Commission; 2006.
4. Huskamp HA. Pharmaceutical cost management and access to psychotropic drugs: the U.S. context. Int J Law Psychiatr. 2005;28(5):484-95.
5. Hearne J. Prescription drug coverage under Medicaid: CRS report for Congress [Internet]. Washington (DC): Congressional Research Service; [updated 2008 Feb 6; cited 2011 Oct 24]. Available from: http://www.aging.senate.gov/crs/medicaid16.pdf
6. Polinski JM, Wang PS, Fischer MA. Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Aff (Millwood). 2007;26(3):750-60.
7. Soumerai SB, Zhang F, Ross-Degnan D, Ball DE, LeCates RF, Law MR, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood). 2008;27(3):w185-95. DOI: 10.1377/hlthaff.27.3.w185.
8. Lu CY, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Med Care. 2010;48(1):4-9.
9. Law MR, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatr Serv. 2008;59:540-6.
10. Farley JF, Cline RR, Schommer JC, Hadsall RS, Nyman JA. Retrospective assessment of Medicaid steptherapy prior authorization policy for atypical antipsychotic medications. Clin Ther. 2008;30(8): 1524-39.
11. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drugreimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650-5.
12. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: metaanalysis. Br J Psychiatry. 2010;197 (3): 174-9.
13. To access the Appendix, click on the Appendix link in the box to the right of the article online
14. Kaiser Family Foundation. State healthfacts.org [home page on the Internet]. Washington (DC): KFF; [cited 2011 Oct 24]. Available from: http://www.statehealthfacts.org
15. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood). 2004;23(1):135-46.
16. Smalley WE, Griffin MR, Fought RL, Sullivan L, Ray WA. Effect of a priorauthorization requirement on the use of nonsteroidal anti-inflammatory drugs by Medicaid patients. N Engl J Med. 1995;332(24):1612-17.
17. Delate T, Mager DE, Sheth J, Motheral BR. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care. 2005;11(1):29-36.
18. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid priorauthorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351(21):2187-94.
19. Hoadley J, Summer L, Hargrave E, Cubanski J, Neuman T. Medicare prescription drug plans in 2010 and key changes over five years: summary of findings [Internet]. Menlo Park (CA): Kaiser Family Foundation; 2010 Sep [cited 2011 Oct 25]. (Medicare Part D 2010 Data Spotlight). Available from: http://www.kff.org/medicare/upload/8096.pdf